secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001628280-23-015494
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma Q1 net loss $24M; cash $94.4M funds ops into Q2 2024; WHIM NDA on track
--------------------------------------------------------------------------------

- Cash, cash equivalents, and restricted cash of $94.4M as of March 31, 2023, sufficient into Q2 2024.
- R&D expenses $22.1M (up from $14.1M YoY) including $5.0M accrual for probable in-licensing milestone.
- Net loss $24.0M vs $22.0M YoY; includes $1.6M stock compensation and $5.4M gain on warrant liability.
- U.S. NDA submission for mavorixafor in WHIM syndrome on track for early second half 2023.
- Phase 2 chronic neutropenia data and regulatory path update anticipated in Q2/Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023015494/0001628280-23-015494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023015494/xfor-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-015494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer